D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study
- PMID: 25560712
- DOI: 10.7326/M14-1275
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study
Abstract
Background: Normal D-dimer levels after withdrawal of anticoagulant therapy are associated with a reduced risk for recurrence in patients with unprovoked venous thromboembolism (VTE) and may justify stopping treatment.
Objective: To determine whether patients with a first unprovoked VTE and negative D-dimer test result who stop anticoagulant therapy have a low risk for recurrence.
Design: Prospective management study with blinded outcome assessment. (ClinicalTrials.gov: NCT00720915).
Setting: 13 university-affiliated clinical centers.
Patients: 410 adults aged 75 years or younger with a first unprovoked proximal deep venous thrombosis or pulmonary embolism who had completed 3 to 7 months of anticoagulant therapy.
Intervention: Anticoagulant therapy was stopped if D-dimer test results were negative and was not restarted if results were still negative after 1 month.
Measurements: Recurrent VTE during an average follow-up of 2.2 years.
Results: In 319 patients (78%) who had 2 negative D-dimer results and did not restart anticoagulant therapy, rates of recurrent VTE were 6.7% (95% CI, 4.8% to 9.0%) per patient-year overall (42 of 319), 9.7% (CI, 6.7% to 13.7%) per patient-year in men (33 of 180), 5.4% (CI, 2.5% to 10.2%) per patient-year in women with VTE not associated with estrogen therapy (9 of 81), and 0.0% (CI, 0.0% to 3.0%) per patient-year in women with VTE associated with estrogen therapy (0 of 58) (P = 0.001 for the 3-group comparison).
Limitations: Imprecision in female subgroups. Results may not be generalizable to different D-dimer assays from the one used in the study.
Conclusion: The risk for recurrence in patients with a first unprovoked VTE who have negative D-dimer results is not low enough to justify stopping anticoagulant therapy in men but may be low enough to justify stopping therapy in women.
Primary funding source: Canadian Institutes of Health Research.
Comment in
-
Idiopathische Venenthrombose: Antikoagulation nach negativem D-Dimer absetzen?Praxis (Bern 1994). 2015 Apr 8;104(8):425-6. doi: 10.1024/1661-8157/a001974. Praxis (Bern 1994). 2015. PMID: 25851373 German. No abstract available.
-
D-Dimer Testing in Patients With a First Unprovoked Venous Thromboembolism.Ann Intern Med. 2015 May 5;162(9):670-1. doi: 10.7326/L15-5089. Ann Intern Med. 2015. PMID: 25939005 No abstract available.
-
D-Dimer Testing in Patients With a First Unprovoked Venous Thromboembolism.Ann Intern Med. 2015 May 5;162(9):671. doi: 10.7326/L15-5089-2. Ann Intern Med. 2015. PMID: 25939006 No abstract available.
Similar articles
-
Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism.Ann Intern Med. 2010 Oct 19;153(8):523-31. doi: 10.7326/0003-4819-153-8-201010190-00009. Ann Intern Med. 2010. PMID: 20956709 Review.
-
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort study.J Thromb Haemost. 2019 Jul;17(7):1144-1152. doi: 10.1111/jth.14458. Epub 2019 May 20. J Thromb Haemost. 2019. PMID: 31033194
-
D-dimer levels and recurrence in patients with unprovoked VTE and a negative qualitative D-dimer test after treatment.Thromb Res. 2016 Oct;146:119-125. doi: 10.1016/j.thromres.2016.06.023. Epub 2016 Jun 23. Thromb Res. 2016. PMID: 27354153
-
Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.Ann Intern Med. 2008 Oct 7;149(7):481-90, W94. doi: 10.7326/0003-4819-149-7-200810070-00008. Ann Intern Med. 2008. PMID: 18838728 Review.
-
Venous thromboembolism: risk factors for recurrence.Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):298-310. doi: 10.1161/ATVBAHA.108.182428. Arterioscler Thromb Vasc Biol. 2009. PMID: 19228602 Review.
Cited by
-
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.BMJ Open. 2024 Mar 23;14(3):e078676. doi: 10.1136/bmjopen-2023-078676. BMJ Open. 2024. PMID: 38521524 Free PMC article.
-
The dos, don'ts, and nuances of thrombophilia testing.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):593-599. doi: 10.1182/hematology.2023000491. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066917
-
Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation.Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):467-473. doi: 10.1182/hematology.2022000401. Hematology Am Soc Hematol Educ Program. 2022. PMID: 36485151 Free PMC article.
-
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study.Blood Adv. 2022 Dec 13;6(23):6005-6015. doi: 10.1182/bloodadvances.2022007973. Blood Adv. 2022. PMID: 35914222 Free PMC article.
-
Increased Prevalence of Elevated D-Dimer Levels in Patients on Direct Oral Anticoagulants: Results of a Large Retrospective Study.Front Cardiovasc Med. 2022 Mar 31;9:830010. doi: 10.3389/fcvm.2022.830010. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35433891 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical